[en] BACKGROUND: Chronic kidney disease (CKD) is diagnosed and explored through the determination of the glomerular filtration rate (GFR). Our goal was to develop a simple LC-MS method for the determination in serum of 2 popular GFR markers, contrast agents iohexol and iothalamate, for routine use and comparison studies between the two markers. A similar contrast agent, ioversol, was used as an internal standard and the method underwent a rigorous validation protocol based on beta-expectation tolerance intervals. METHODS: We adapted the HPLC-UV method from Cavalier et al. to our LC-MS system. Data treatment for the validation was performed using Multiquant 3.0 (Sciex, Framingham, MA, USA) and e.noval 3.0 software (Arlenda, Liege, Belgium). RESULTS: According to the validation results our method will give accurate and reliable results for concentrations ranging from 6.8 to 250mug/ml for iohexol and 6.15mug/ml to 250mug/ml for iothalamate. In our practice these intervals are sufficient to determine both compounds in most patient samples. Samples with higher detected concentrations can always be diluted into range. CONCLUSION: With its internal standard and extensive validation, our method is now ready for routine and clinical research use.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Nyssen, Laurent ; Université de Liège > Département de pharmacie > Chimie médicale
DELANAYE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie
Le Goff, Caroline ; Université de Liège > Département de pharmacie > Chimie médicale
PEETERS, Stéphanie ; Centre Hospitalier Universitaire de Liège - CHU > Service de chimie clinique
Cavalier, Etienne ; Université de Liège > Département de pharmacie > Chimie médicale
Language :
English
Title :
A simple LC-MS method for the determination of iohexol and iothalamate in serum, using ioversol as an internal standard.
[1] Smith, H., The Kidney - Structure and Function in Health and Disease. 1951, Oxford University Press, New York.
[2] National Kidney Foundation, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39 (2002), S1–266 http://www.ncbi.nlm.nih.gov/pubmed/11904577.
[3] Delanaye, P., How measuring glomerular filtration rate? Comparison of reference methods. Basic Nephrology Acute Kidney Injury, 2012, InTech, 10.5772/25770.
[4] Botev, R., Mallie, J.-P., Couchoud, C., Schuck, O., Fauvel, J.-P., Wetzels, J.F.M., Lee, N., De Santo, N.G., Cirillo, M., Estimating glomerular filtration rate: Cockcroft-Gault and modification of diet in renal disease formulas compared to renal inulin clearance. Clin. J. Am. Soc. Nephrol. 4 (2009), 899–906, 10.2215/CJN.05371008.
[5] Botev, R., Mallie, J.-P., Wetzels, J.F.M., Couchoud, C., Schuck, O., The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis. Clin. J. Am. Soc. Nephrol. 6 (2011), 937–950, 10.2215/CJN.09241010.
[6] Perrone, R.D., Madias, N.E., Levey, A.S., Serum creatinine as an index of renal function: new insights into old concepts. Clin. Chem. 38 (1992), 1933–1953 ( http://www.ncbi.nlm.nih.gov/pubmed/1394976).
[7] Mariat, C., Maillard, N., Phayphet, M., Thibaudin, L., Laporte, S., Alamartine, E., Berthoux, F., Estimated glomerular filtration rate as an end point in kidney transplant trial: where do we stand?. Nephrol. Dial. Transplant. 23 (2007), 33–38, 10.1093/ndt/gfm708.
[8] Delanaye, P., Lambermont, B., Chapelle, J.-P., Gielen, J., Gerard, P., Rorive, G., Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units. Intensive Care Med. 30 (2004), 980–983, 10.1007/s00134-004-2189-5.
[10] Stevens, L.A., Levey, A.S., Measured GFR as a confirmatory test for estimated GFR. J. Am. Soc. Nephrol. 20 (2009), 2305–2313, 10.1681/ASN.2009020171.
[11] Soveri, I., Berg, U.B., Björk, J., Elinder, C.-G., Grubb, A., Mejare, I., Sterner, G., Bäck, S.-E., Measuring GFR: a systematic review. Am. J. Kidney Dis. 64 (2014), 411–424, 10.1053/j.ajkd.2014.04.010.
[12] Van Pottelbergh, G., Hoste, L., Degryse, J., Pottel, H., Claes, K., Demoulin, N., Jadoul, M., Bammens, B., Wallemacq, P., Measuring the glomerular filtration rate in different age groups using iohexol, the protocol from the Belgian iohexol study. Clin. Biochem. 46 (2013), 31–36, 10.1016/j.clinbiochem.2012.10.017.
[13] Gaspari, F., Perico, N., Ruggenenti, P., Mosconi, L., Amuchastegui, C.S., Guerini, E., Daina, E., Remuzzi, G., Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J. Am. Soc. Nephrol. 6 (1995), 257–263 ( http://www.ncbi.nlm.nih.gov/pubmed/7579093).
[14] Vicente, F.B., Vespa, G.K., Carrara, F., Gaspari, F., Haymond, S., Determination of iohexol in human serum by a semi-automated liquid chromatography tandem mass spectrometry method. Clin. Biochem. 48 (2015), 679–685, 10.1016/j.clinbiochem.2015.03.017.
[15] Frennby, B., Sterner, G., Contrast media as markers of GFR. Eur. Radiol. 12 (2002), 475–484, 10.1007/s003300100864.
[16] Brown, S.C., O'Reilly, P.H., Iohexol clearance for the determination of glomerular filtration rate in clinical practice: evidence for a new gold standard. J. Urol. 146 (1991), 675–679 ( http://www.ncbi.nlm.nih.gov/pubmed/1875470).
[18] Morcos, S.K., Prevention of contrast media-induced nephrotoxicity after angiographic procedures. J. Vasc. Interv. Radiol. 16 (2005), 13–23, 10.1097/01.RVI.0000145224.02920.C2.
[19] Thomsen, H.S., Guidelines for contrast media from the European Society of Urogenital Radiology. Am. J. Roentgenol. 181 (2003), 1463–1471, 10.2214/ajr.181.6.1811463.
[20] Hasebroock, K.M., Serkova, N.J., Toxicity of MRI and CT contrast agents. Expert Opin. Drug Metab. Toxicol. 5 (2009), 403–416, 10.1517/17425250902873796.
[21] Steinberg, E.P., Moore, R.D., Powe, N.R., Gopalan, R., Davidoff, A.J., Litt, M., Graziano, S., Brinker, J.A., Safety and cost effectiveness of high-osmolality as compared with low-osmolality contrast material in patients undergoing cardiac angiography. N. Engl. J. Med. 326 (1992), 425–430, 10.1056/NEJM199202133260701.
[22] Davidson, C., Stacul, F., McCullough, P.A., Tumlin, J., Adam, A., Lameire, N., Becker, C.R., Contrast medium use. Am. J. Cardiol. 98 (2006), 42–58, 10.1016/j.amjcard.2006.01.023.
[23] Cavalier, E., Rozet, E., Dubois, N., Charlier, C., Hubert, P., Chapelle, J.-P., Krzesinski, J.-M., Delanaye, P., Performance of iohexol determination in serum and urine by HPLC: validation, risk and uncertainty assessment. Clin. Chim. Acta 396 (2008), 80–85, 10.1016/j.cca.2008.07.011.
[24] Annesley, T.M., Clayton, L.T., Ultraperformance liquid chromatography-tandem mass spectrometry assay for iohexol in human serum. Clin. Chem. 55 (2009), 1196–1202, 10.1373/clinchem.2008.121533.
[25] Rhea, J.M., Ritchie, J.C., Molinaro, R.J., Development of a liquid chromatography tandem mass spectrometry method for iothalamate measurement to assess renal function for potential kidney donation. Clin. Chim. Acta 420 (2013), 104–108, 10.1016/j.cca.2012.12.003.
[26] Schulz, A., Boeringer, F., Swifka, J., Kretschmer, A., Schaefer, M., Jankowski, V., van der Giet, M., Schuchardt, M., Toelle, M., Tepel, M., Schlieper, G., Zidek, W., Jankowski, J., A highly sensitive method for quantification of iohexol. Anal. Methods, 6, 2014, 3706, 10.1039/c4ay00174e.
[27] Delanaye, P., Jouret, F., Le Goff, C., Cavalier, E., Concordance between iothalamate and iohexol plasma clearance. Am. J. Kidney Dis. 68 (2016), 329–330, 10.1053/j.ajkd.2016.01.007.
[28] Seegmiller, J.C., Burns, B.E., Schinstock, C.A., Lieske, J.C., Larson, T.S., Discordance between iothalamate and iohexol urinary clearances. Am. J. Kidney Dis. 67 (2016), 49–55, 10.1053/j.ajkd.2015.08.020.
[29] ISO 5725-1, Application of the Statistics - Accuracy (Trueness and Precision) of the Results and Methods of Meassurement - Part 1: General Principles and Definitions. 2005, International Organisation for Standardisation (ISO), Geneva.
[30] Hubert, P., Nguyen-Huu, J.-J., Boulanger, B., Chapuzet, E., Chiap, P., Cohen, N., Compagnon, P.-A., Dewé, W., Feinberg, M., Lallier, M., Laurentie, M., Mercier, N., Muzard, G., Nivet, C., Valat, L., Harmonization of strategies for the validation of quantitative analytical procedures. J. Pharm. Biomed. Anal. 36 (2004), 579–586, 10.1016/j.jpba.2004.07.027.
[31] International Vocabulary of Basic and General Terms in Metrology. 1993, International Organisation for Standardisation (ISO), Geneva.
[32] International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q2 R1: Validation of Analytical Procedures - Text and Methodology. Geneva, 2005.
[33] Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Rockville, 2001.
[34] The Fitness for Purpose of Analytical Methods: A Laboratory Guide to Method Validation and Related Topics. 1998, Eurachem, Teddington.
[35] Feinberg, M., Boulanger, B., Dewé, W., Hubert, P., New advances in method validation and measurement uncertainty aimed at improving the quality of chemical data. Anal. Bioanal. Chem. 380 (2004), 502–514, 10.1007/s00216-004-2791-y.
[36] EURACHEM/CITAC Guide CG 4, Quantifying Uncertainty in Analytical Measurement. third edition, 2012.
[37] Vardeman, S.B., What about the other intervals?. Am. Stat., 46, 1992, 193, 10.2307/2685212.
[38] Hahn, G.J., Meeker, W.Q., Statistical Intervals: A Guide for Practitioners. 1991, Wiley.
[39] Rozet, E., Ceccato, A., Hubert, C., Ziemons, E., Oprean, R., Rudaz, S., Boulanger, B., Hubert, P., Analysis of recent pharmaceutical regulatory documents on analytical method validation. J. Chromatogr. A 1158 (2007), 111–125, 10.1016/j.chroma.2007.03.111.
[40] Rozet, E., Morello, R., Lecomte, F., Martin, G.B., Chiap, P., Crommen, J., Boos, K.S., Hubert, P., Performances of a multidimensional on-line SPE-LC-ECD method for the determination of three major catecholamines in native human urine: validation, risk and uncertainty assessments. J. Chromatogr. B 844 (2006), 251–260, 10.1016/j.jchromb.2006.07.060.
[41] Linko, S., Örnemark, U., Kessel, R., Taylor, P.D.P., Evaluation of uncertainty of measurement in routine clinical chemistry - applications to determination of the substance concentration of calcium and glucose in serum. Clin. Chem. Lab. Med. 40 (2002), 391–398, 10.1515/CCLM.2002.063.
[42] Rozet, E., Hubert, C., Ceccato, A., Dewé, W., Ziemons, E., Moonen, F., Michail, K., Wintersteiger, R., Streel, B., Boulanger, B., Hubert, P., Using tolerance intervals in pre-study validation of analytical methods to predict in-study results. J. Chromatogr. A 1158 (2007), 126–137, 10.1016/j.chroma.2007.03.102.
[43] Denis, M.C., Venne, K., Lesiège, D., Francoeur, M., Groleau, S., Guay, M., Cusson, J., Furtos, A., Development and evaluation of a liquid chromatography–mass spectrometry assay and its application for the assessment of renal function. J. Chromatogr. A 1189 (2008), 410–416, 10.1016/j.chroma.2007.12.061.
[44] Seegmiller, J.C., Burns, B.E., Fauq, A.H., Mukhtar, N., Lieske, J.C., Larson, T.S., Iothalamate quantification by tandem mass spectrometry to measure glomerular filtration rate. Clin. Chem. 56 (2010), 568–574, 10.1373/clinchem.2009.133751.
[45] El-Khoury, J.M., Gabler, J., Wang, S., Measurement of GFR for children and an LC–MS/MS method for nonradioactive iothalamate. Clin. Biochem. 47 (2014), 749–750, 10.1016/j.clinbiochem.2014.05.042.
[46] Van Houcke, S.K., Seaux, L., Cavalier, E., Speeckaert, M.M., Dumoulin, E., Lecocq, E., Delanghe, J.R., Determination of iohexol and iothalamate in serum and urine by capillary electrophoresis. Electrophoresis 37 (2016), 2363–2367, 10.1002/elps.201600084.
[47] Soman, R.S., Zahir, H., Akhlaghi, F., Development and validation of an HPLC-UV method for determination of iohexol in human plasma. J. Chromatogr. B 816 (2005), 339–343, 10.1016/j.jchromb.2004.11.046.
